Skip to main content

Summary

for people ages 13 years and up (full criteria)
at San Francisco, California and other locations
study started

Description

Summary

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Official Title

A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis

Keywords

Pruritus Atopic Dermatitis Serlopitant

Eligibility

You can join if…

Open to people ages 13 years and up

  • Male or female, age 13 years or older
  • Pruritus prior to and during the initial screening period
  • Diagnosis of atopic dermatitis
  • Judged to be in good health in the investigator's opinion

You CAN'T join if...

  • Prior treatment with study drug or similar drug
  • Pruritus due to another reason besides atopic dermatitis
  • Presence of any medical condition or disability that could interfere with study
  • History of hypersensitivity to serlopitant or any of its components
  • Currently pregnant or male partner of pregnant female
  • Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding

Locations

  • Study Site 333 accepting new patients
    San Francisco, California, United States
  • Study Site 376 accepting new patients
    Santa Monica, California, United States
  • Study Site 338 accepting new patients
    Los Angeles, California, United States
  • Study Site 334 accepting new patients
    Cerritos, California, United States
  • Study Site 366 accepting new patients
    Fountain Valley, California, United States
  • Study Site 374 accepting new patients
    Oceanside, California, United States

Details

Status
accepting new patients
Start Date
Sponsor
Menlo Therapeutics Inc.
ID
NCT02975206
Phase
Phase 2
Lead Scientist
Sarah Arron
Study Type
Interventional
Last Updated
May 1, 2017
I’m interested in this study!